Open-label Single-arm Study to Assess the Efficacy of Mirikizumab in Patients With Inflammatory Strictures Due to CD | MicrobiomeTrials← Back to trialsNCT06997965
Open-label Single-arm Study to Assess the Efficacy of Mirikizumab in Patients With Inflammatory Strictures Due to CD
RecruitingPHASE4INTERVENTIONAL
Trial Details
Start: 2026-04-20Est. Completion: 2027-09-01
Enrollment target: 60 participants Locations- University of Miami, Miami, Florida, United States
- Digestive & Liver Center of Florida, Orlando, Florida, United States
- University of Chicago Medicine, Chicago, Illinois, United States
- Velocity Clinical- Salt Lake City, Salt Lake City, Utah, United States
- GI Institute Research Foundation, Vancouver, British Columbia, Canada
- McMaster University Medical Center, Hamilton, Ontario, Canada
- London Digestive Disease Institute, London, Ontario, Canada
- The Office of Dr. Jason Reinglas, Scarborough Village, Ontario, Canada
Other microbiome trials you might be interested in
Inflammatory Bowel Diseases (IBD)Crohn DiseaseColitis, Ulcerative
Difficult-to-treat inflammatory bowel disease (DTT-IBD) represents a heterogeneous group of patients with treatment-refr…
Multiple LocationsEst. completion Oct 31, 2032
Inflammatory Bowel Disease
This study evaluates oral Lactobacillus reuteri as an adjunct therapy for 2 months. Endoscopic assessments will be perfo…
Suqian, ChinaCompleted Mar 30, 2026